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INTRODUCTION
The reversibility of bronchoconstriction with β2-adrenergic 
agonists and increased airway responsiveness to a variety of 
stimuli are hallmarks of asthma.
1 Current treatment guidelines 
recommend the use of inhaled corticosteroids and β2-adrenergic 
agonists for individuals with mild to moderate persistent asth-
ma.
2 However, acute asthma attacks caused by extensive airway 
obstruction following airway smooth muscle constriction some-
times occur in patients receiving asthma medications.
3 Inhaled 
short-acting β2-adrenergic agonists (SABAs) play an important 
role in the treatment of acute bronchoconstriction.
4
Bronchodilator responsiveness (BDR) is the improvement of 
forced expiratory volume in 1 second (FEV1) after inhalation of 
β2-agonists and is typically measured as the change in airflow 
after the administration of SABAs. BDR is commonly used to 
assess the severity of asthma and to guide pharmacological 
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treatment. However, the responses to inhaled β2-adrenergic ag-
onists can be highly variable.
5
Airway hyper-responsiveness (AHR), defined as an exaggerat-
ed bronchoconstrictive response of the airways to the numer-
ous stimuli that provoke bronchial obstruction and inflamma-
tion, is a characteristic feature of asthma.
6-8 The evaluation of 
AHR is useful for the diagnosis of asthma, the determination of 
asthma severity, and the therapeutic responses to bronchodila-
tors. Methacholine inhalation elicits acute bronchial obstruc-
tion in individuals with asthma, in part by direct cholinergic 
stimulation. Thus, the reversal of methacholine-induced bron-
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Purpose:  The aim of this study was to investigate bronchodilator responsiveness (BDR) following methacholine-induced bronchoconstriction and 
to determine differences in BDR according to clinical parameters in children with asthma.  Methods:  The methacholine challenge test was per-
formed in 145 children with mild to moderate asthma, and the provocative concentration causing a 20% decline in FEV1 (PC20) was determined. Im-
mediately after the challenge test, patients were asked to inhale short-acting β2-agonists (SABAs) to achieve BDR, which was assessed as the 
change in FEV1% predicted×100/post-methacholine FEV1% predicted. For each subject, the asthma medication, blood eosinophil count, serum to-
tal IgE, serum eosinophil cationic protein level, and skin prick test result were assessed.  Results:  The FEV1 (mean±SD) values of the 145 patients 
were 90.5±10.9% predicted, 64.2±11.5% predicted, and 86.2±11.2% predicted before and after methacholine inhalation, and following the ad-
ministration of a SABA, respectively. The BDR did not differ significantly according to asthma medication, age, or gender. However, BDR in the atopy 
group (37.4±17.7%) was significantly higher than that in the non-atopy group (30.5±10.7%; P=0.037). Patients with blood eosinophilia (38.6±
18.1%) displayed increased BDR compared with patients without eosinophilia (32.0±13.8%; P=0.037).  Conclusions:  In children with mild to 
moderate asthma, the responsiveness to short-acting bronchodilators after methacholine-induced bronchoconstriction was not related to asthma 
medication, but was higher in children with atopy and/or peripheral blood eosinophilia.
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choconstriction by bronchodilators is a useful and standard-
ized model for the determination of airway responsiveness to 
bronchodilators.
9,10
The knowledge of factors affecting BDR in children with asth-
ma is limited. Understanding the implications of a response to 
a bronchodilator may help clinicians to more effectively assess 
asthma treatment regimens in the outpatient setting. The aim 
of this study was to determine the response to bronchodilators 
after methacholine-induced bronchoconstriction and to inves-
tigate the relationship between BDR and clinical parameters in 
children with mild to moderate asthma.
MATERIALS AND METHODS
Study subjects
Children, aged 6-18 years, who had physician-diagnosed mild 
to moderate asthma and a history of episodic wheezing and/or 
dyspnea that resolved with bronchodilators during the previ-
ous year were enrolled in this study (n=145). The patients were 
followed at the allergy clinic of the Anam Hospital of Korea Uni-
versity. The clinical severity of asthma was assessed according 
to the National Asthma Education and Prevention Program.
11 
Treatment included inhaled SABAs on demand for the relief of 
symptoms, with or without control medications; inhaled corti-
costeroids; leukotriene receptor antagonists; or inhaled long-
acting β2-agonists (LABAs). Patients with a history of near-fatal 
asthma, major exacerbations necessitating the use of systemic 
corticosteroids, or other respiratory diseases were excluded 
from the study.
Parents provided written informed consent for their children 
to participate in the study. The study protocol was approved by 
the Institutional Review Board of Anam Hospital.
Pulmonary function tests
Spirometry (FEV1 and forced vital capacity [FVC]) was per-
formed using a computerized spirometer (Microspiro-HI 298; 
Chest; Tokyo, Japan), in accordance with the recommenda-
tions of the American Thoracic Society.
12 All patients were re-
quired to achieve a FEV1 of at least 70% of the predicted value.
Methacholine challenge test
Following the establishment of a baseline spirometry value, 
all patients underwent bronchoprovocation with increasing 
concentrations of methacholine. Methacholine inhalation tests 
were performed using a modification of the method described 
by Chai et al.
13 At the time of the test, all patients had been free 
of acute respiratory tract infection and asthma exacerbation for 
4 weeks. All patients were asked to discontinue the use of any 
inhaled SABA for 24 hours, and any inhaled LABA or cortico-
steroid for 7 days prior to the test. Methacholine (Sigma Diag-
nostics, St. Louis, MO, USA) solutions were prepared at concen-
trations of 0.075, 0.15, 0.3, 0.625, 1.25, 2.5, 5, 10, and 25 mg/mL 
in buffered saline solution (pH 7.4). A Rosenthal-French dosim-
eter (Laboratory for Applied Immunology, Baltimore, MD, USA), 
triggered by a solenoid valve set to remain open for 0.6 second, 
was used to administer an aerosol from a DeVilbiss 646 nebu-
lizer (DeVilbiss Health Care, Somerset, PA, USA) with pressur-
ized air at 20 psi. Each patient performed inhalations of five in-
spiratory capacity breaths of buffered saline solution contain-
ing increasing concentrations of methacholine, at 5-minute in-
tervals. This gave an output of 0.009±0.0014 mL (mean±SD) 
per inhalation. The FEV1 and FVC were measured 90 seconds 
after inhalation of each concentration, and the largest of tripli-
cate FEV1 or FVC values was used for the analysis. The proce-
dure was terminated when the FEV1 decreased by more than 
20% of the post-saline value or when the highest methacholine 
concentration (25 mg/mL) was reached. The percentage de-
cline of the FEV1 from the post-saline value was plotted against 
the log concentration of inhaled methacholine. The provoca-
tive concentration (PC20) and provocative cumulative dose of 
methacholine producing a 20% fall in FEV1 (PD20) were calcu-
lated by interpolating between two adjacent data points. The 
total cumulative dose (c.u.), one dose unit being one inhalation 
of 1 mg/mL of methacholine, was calculated. All patients dis-
played a PC20 of less than 16 mg/mL.
Measurement of bronchodilator response
Immediately after the cessation of methacholine upon a fall in 
FEV1 to more than 20% of the post-saline value, a bronchodila-
tor responsiveness test to inhaled salbutamol (Ventolin Evohal-
er; GlaxoSmithKline, London, UK) was performed. Four sepa-
rate doses of salbutamol (400 µg) were administered from a 
metered dose inhaler via a spacer (AeroChamber Plus; Trudell 
Medical International, Ontario, Canada); spirometry was per-
formed after 15 minutes (post-BD FEV1 and post-BD FVC). The 
BDR was defined as the change in FEV1% predicted×100/post-
methacholine FEV1% predicted.
14
Skin prick test
The skin prick test was performed using 13 common aeroal-
lergens, and atopy was defined as the presence of at least one 
positive reaction (mean wheal diameter of >3 mm) to these al-
lergens.
Measurement of peripheral blood eosinophil counts, serum 
total IgE, and eosinophil cationic protein concentrations
The number of peripheral blood eosinophils was counted 
from blood samples containing EDTA, using an automated he-
matology analyzer (Coulter Counter STKS; Beckman Coulter, 
Fullerton, CA, USA). The serum total IgE level was measured 
using a Coat-A-Count Total IgE IRMA (Diagnostic Products Co., 
Los Angeles, CA, USA) according to the manufacturer’s instruc-
tions. The serum eosinophil cationic protein (ECP) level was 
measured using a commercially available fluoroimmunoassay BDR Following Induced Bronchoconstriction
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kit (Pharmacia ECP UniCAP System FEIA; Pharmacia Diagnos-
tics, Uppsala, Sweden) with a detection limit of less than 2.0 µg/L.
Statistical analysis
Both FEV1 and FVC were expressed as a percentage of the 
predicted value based on data from our local population. The 
values for PC20, PD20, blood eosinophil counts, serum total 
IgE, and serum ECP were log transformed prior to statistical 
analysis. Data are presented as means±SD. Variables were 
compared between two groups using Student’s t-test or a chi-
squared test, as appropriate. One-way ANOVA and a post hoc 
test were performed to account for asthma medication-related 
differences in baseline FEV1, the fall in FEV1 during methacho-
line challenge (∆FEV1), post-BD FEV1, and BDR. All statistical 
analyses were performed using SPSS software (SPSS Inc., Chi-
cago, IL, USA). Values of P<0.05 were considered to indicate 
statistical significance.
RESULTS
A total of 145 children with asthma were enrolled in this study. 
The clinical characteristics of the subjects are shown in Table 1. 
Among the 145 patients, 23 used an inhaled SABA, 29 received 
a leukotriene receptor antagonist, 32 received an inhaled corti-
costeroid, and 61 received the combination of an inhaled corti-
costeroid plus a LABA to relieve asthma symptoms. The mean 
(±SD) age of the patients was 9.4 (±2.7) years.
Table 2 shows the pulmonary function parameters of the pa-
tients. The FEV1 values (mean±SD) were 90.5±10.9% predict-
ed, 64.2±11.5% predicted, and 86.2±11.2% predicted before 
and after methacholine inhalation, and after SABA administra-
tion, respectively.
The bronchodilator responsiveness and methacholine inhaled 
dose are shown in Table 3. The mean (±SD) percentage reduc-
tion of FEV1 after methacholine inhalation was 29.2±8.1%, and 
the mean (±SD) BDR was 36.7±17.0%. A total of 109 patients 
(75.2%) recovered to >90% of the pre-challenge FEV1 value. The 
geometric means (range of 1 SD) of the methacholine PC20 and 
total methacholine inhaled dose were 2.60 (range, 0.66–10.3) 
mg/mL and 33.9 (range, 8.13–141.3) c.u., respectively.
The FEV1% predicted values before and after methacholine 
challenge and after bronchodilator use as well as the BDR did 
not differ significantly according to the asthma medication 
used (Fig. 1).
The pre- and post-methacholine and post-BD FEV1 did not 
Table 1. Clinical characteristics of the children with asthma
Characteristic Data
Age (yr)* 9.4±2.7
Gender (boy/girl) 87/58
BMI (kg/m
2)* 18.7±3.4
Atopy, n (%)
† 124 (85.5)
Serum total IgE (IU/mL)
‡ 242.1 (range, 58.9–992.2)
Asthma medications
§ (23/29/32/61)
Blood eosinophil count ≥4%, n (%) 96 (66.2)
Eosinophil cationic protein (µg/mL)
‡ 22.5 (range, 7.82–64.7)
*Mean±SD; 
†Defined as positive skin prick test; 
‡Geometric mean (range of 1 
SD); 
§As required, inhaled short acting β2-agonists/leukotriene receptor antag-
onists/inhaled corticosteroids/inhaled corticosteroids+long acting β2-agonist.
BMI, body mass index.
Table 3. Bronchodilator responsiveness and inhaled methacholine dose of the 
children with asthma
Parameter Data
∆FEV1 following methacholine (%)* 29.2±8.1
BDR (%) 36.7±17.0
Recovered ≥90% of baseline FEV1, n (%)
† 109 (75.2)
PC20 (mg/mL)
‡  2.60 (range, 0.66–10.3)
PD20 (mg)
‡ 23.5 (range, 49.0–112.7)
Methacholine inhaled (c.u.)
‡ 33.9 (range, 8.13–141.3)
*Mean±SD; 
†Subjects recovering to ≥90% of baseline FEV1; 
‡Geometric mean 
(range of 1 SD).
FEV1, forced expiratory volume in 1 sec; BDR, bronchodilator responsiveness; 
PC20; provocative concentration of methacholine causing a 20% decline in 
FEV1; PD20, provocative cumulative dose of methacholine causing a 20% de-
cline in FEV1.
Table 2. Post-methacholine and post-bronchodilator pulmonary function pa-
rameters of the children with asthma
Parameter Baseline Post-methacholine Post-salbutamol
FEV1% predicted* 90.5±10.9 64.2±11.5 86.2±11.2
FVC% predicted* 92.3±10.6 76.6±12.9 88.8±11.3
FEV1/FVC (%)* 83.7±6.8 71.9±8.3 83.1±6.3
*Mean±SD.
FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity.
Fig. 1. FEV1% predicted before methacholine, after methacholine (last concen-
tration), and 15 min after bronchodilator administration, and bronchodilator re-
sponsiveness (BDR) according to asthma medication. ■, inhaled short-acting 
β2-agonists on demand; ■, leukotriene receptor antagonists; ■, inhaled cor-
ticosteroids alone; ■ inhaled long-acting β2-agonists and corticosteroid com-
bination.
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differ between the atopic and non-atopic patients, although the 
BDR was significantly higher in atopic subjects compared with 
non-atopic subjects (37.4±17.7% vs. 30.5±10.7%, respectively; 
P=0.037; Fig. 2). Children who displayed peripheral blood eo-
sinophil counts of ≥4% showed significantly higher BDR than 
those with eosinophil counts of <4% (38.6±18.1% vs. 32.0±
13.8%, respectively; P=0.037; Fig. 3).
 
DISCUSSION
The assessment of responsiveness to bronchodilators is es-
sential for the diagnosis and treatment of asthma. Current treat-
ment guidelines recommend the use of an inhaled SABA to re-
lieve symptoms in individuals with mild to moderate asthma.
2 
In the present study, the BDR and the clinical factors that may 
affect BDR were evaluated in children with mild to moderate 
asthma. Asthmatic patients with atopy and/or eosinophilia dis-
played an increased responsiveness to bronchodilators after 
methacholine-induced bronchoconstriction.
BDR is typically assessed as the change in airflow before ver-
sus after the administration of a β2-agonist; however, the base-
line airway tone may influence BDR.
14 It is expected that airflow 
would not increase if the airways at baseline were fully dilated 
by asthma treatment. The present study addressed this issue by 
measuring BDR following methacholine-induced bronchocon-
striction. This challenge-rescue method of bronchodilation mea-
surement was suggested in the 1970s as a method for overcom-
ing the variability in FEV1 prior to measuring bronchodila-
tion.
15 In addition, chemical challenges such as the methacho-
line test have the advantages of being easily controlled, using 
standard doses, and producing immediate bronchoconstric-
tion.
16 However, as these situations may differ from the actual 
clinical setting, it is reasonable to question the relevance of this 
artificial model of bronchoconstriction and bronchodilation to 
a real asthma attack. Several studies
9,10,17,18 have demonstrated 
that methacholine-induced bronchoconstriction and its rever-
sal by inhaled bronchodilators is a useful and standardized 
model for estimating the effectiveness of bronchodilators.
In this study, BDR was defined as the change in FEV1% pre-
dicted over the pre-bronchodilator value, which has been sug-
gested to be the best of several indices of bronchodilator re-
sponse because it accounts for the confounding effects of 
height, gender, and pre-bronchodilator FEV1.
14,19-21 The mean 
BDR in this study was 36.7%, which is comparable to previously 
reported BDR values of >30% after methacholine-induced 
bronchoconstriction in asthmatic patients.
9,22
For the determination of BDR in the present study, the pa-
tients were instructed to inhale 400 µg of salbutamol. Although 
800 µg of salbutamol have been administered to obtain near 
maximal bronchodilation,
23 the generally recommended dose 
for BDR determination is 400 µg.
24 However, residual airflow 
limitations may exist, which could explain our finding that the 
mean post-BD FEV1 was slightly lower than the mean pre-chal-
lenge baseline FEV1. This may occur because of variable geo-
metric factors, including hypertrophy or hyperplasia of the mu-
cous glands and smooth muscle, interstitial edema, and thick-
ening of the reticular lamina, which are not acutely influenced 
by smooth muscle relaxants.
19
An interesting finding of this study is the higher BDR observed 
in the atopic group compared with the non-atopic group. The 
reason for this difference is not clear. Previous studies have not 
reported a correlation between BDR and atopy among children 
from families with asthma or the general population,
25 while 
other studies have described a significantly higher BDR in adults 
with atopic asthma than in those with non-atopic asthma.
26 In 
one study, asthmatic children with atopy displayed a higher 
BDR than those without atopy, but the difference was not sta-
tistically significant.
27 These discrepancies may be attributable 
to differences among the doses of inhaled SABAs or patient se-
lection. In previous studies, 200 µg of a SABA were used in pa-
tients with stable asthma who did not display reduced FEV1. 
Although it has been suggested that atopy and BDR have inde-
Fig. 2. FEV1% predicted before methacholine, after methacholine (last concen-
tration), and 15 min after bronchodilator administration, and bronchodilator re-
sponsiveness (BDR) according to the presence (■) or absence (■) of atopy.
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Fig. 3. FEV1% predicted before methacholine, after methacholine (last concen-
tration), and 15 min after bronchodilator administration, and bronchodilator re-
sponsiveness (BDR) based on blood eosinophil count. ■, ≥ 4%; ■, < 4%.
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pendent patterns of inheritance, the presence of atopy may cor-
relate with the increased airway responsiveness that follows 
bronchodilator inhalation.
The present finding of higher BDR in patients with high blood 
eosinophil counts is consistent with previous observations. Sil-
vestri et al.
27 reported a significant positive relationship between 
salbutamol-induced changes in FEV1% and blood eosinophilia 
in 92 children with asthma. A study of serial bronchial biopsy 
specimens from nine patients with asthma demonstrated a sig-
nificant correlation between changes in BDR and changes in 
eosinophil counts after 8 weeks of inhaled corticosteroid thera-
py.
28 Furthermore, in adult asthmatics, the response to a β2-
agonist was closely related to the absolute number of eosin-
ophilis in the peripheral blood.
29 These results suggest that an 
increased number of eosinophils is not a direct marker of re-
versibility and that BDR may be a marker for inflammation.
30
Another point of discussion is the dose of methacholine ad-
ministered. As subjects with a higher methacholine reactivity 
received a lower dose of methacholine to achieve the same lev-
el of bronchoconstriction, it is possible that the higher BDR in 
these patients was a reflection of the lower levels of broncho-
constrictive agent received.
9 It can be argued that the differenc-
es in BDR observed in this study are due to the different doses 
of methacholine inhaled. However, this is unlikely because the 
doses of methacholine did not differ among the patient sub-
groups. In contrast, subjects with eosinophilia or atopy displayed 
lower PC20 (data not shown). A higher BDR in these groups was 
more likely to be directly associated with a lower PC20, rather 
than eosinophila. Nevertheless, it is clear that patients with eo-
sinophilia or atopy exhibited a much greater response to bron-
chodilators after induced bronchoconstriction.
BDR did not differ according to the asthma medication. In 
this study, immediately after methacholine challenge, the FEV1 
decreased by 30%, corresponding to a moderate to severe asth-
ma attack, with no apparent differences among the medication 
subgroups. A larger reduction in lung function can occur with 
acute severe asthma attacks, and the loss of responsiveness to 
bronchodilators most likely corresponds to a greater degree.
18,30 
Although a failure to respond to bronchodilators may also be 
associated with other factors such as airway mucus plugging 
and mucosal edema,
31 the results of this study indicate reduced 
BDR with acute asthma exacerbation in non-atopic and/or 
non-eosinophilic patients.
Low BDR indicates a persistent airflow limitation during an 
acute asthma attack. The pre-challenge baseline FEV1 in non-
atopic or non-eosinophilic patients did not differ from that in 
the atopic or eosinophilia group. In addition, a low post-BD 
FEV1/FVC, an index of airway remodeling in patients with 
asthma, was not observed in these groups, meaning that fixed 
airway obstruction can be excluded.
32 At present, the guidelines 
recommend a SABA for treatment of episodic bronchoconstric-
tion. We believe it is important that clinicians are aware of the 
asthma patient parameters related to effective bronchodilator 
responsiveness. This information will be helpful in current pa-
tient treatment regimens.
In conclusion, the results of this study show that the response 
to a bronchodilator after methacholine-induced bronchocon-
striction differed between atopic and non-atopic asthmatic pa-
tients and varied according to the presence of blood eosino-
philia. These results raise the possibility of a reduced broncho-
dilator response in the clinical setting of a severe asthma attack, 
particularly in patients without atopy and/or eosinophilia.
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